Skip to main content
. 2022 Dec 22;24(1):209. doi: 10.3390/ijms24010209

Table A2.

American College of Medical Genetics and Genomics criteria.

Code Description
PVS1 Null variant (nonsense, frameshift, canonical ±1 or 2 splice sites, initiation codon, single or multiexon deletion) in a gene where LOF is a known mechanism of disease.
PS1 Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
PS2 De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
PS3 Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
BS1 Allele frequency is greater than expected for disorder.
PM1 Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation.
PM2 Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium.
PM3 For recessive disorders, detected in trans with a pathogenic variant
PM4 Protein length changes as a result of in-frame deletions/insertions in a non-repeat region or stop-loss variants.
PM5 Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
PP1 Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease.
PP2 Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease.
PP3 Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.)
PP5 Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
BP4 Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.)
BP6 Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.